ReviewMolecular biology reports2025
Hematopoietic stem cells and HSCs-derived from pluripotent stem cells: a hopeful outlook in cell-based therapeutics.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The puzzling duality of mesenchymal stem cells and adipocytes in bone marrow and ageing.npj aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, hematopoietic stem cell transplantation (HSCT) and hematopoietic cell transfusion are the accepted therapy for patients with both malignant and nonmalignant hematological disorders. Due to the limited availability of donors and hematopoietic cells, the generation of hematopoietic cells from pluripotent stem cells (PSCs) is considered as a promising alternative source for hematopoietic cells in therapeutic applications. PSCs are undifferentiated cells capable of both self-renewal and differentiation into various hematopoietic lineages, including HSCs, hematopoietic progenitor cells (HPCs), and adult hematopoietic cells in vitro, offer significant potential. Therefore, ex vivo production of patient-specific hematopoietic stem cells (HSCs) derived from renewable sources such as PSCs serves as an experimental tool for investigating the field of regenerative medicine research and can be utilized for treating hematological diseases, especially when no other options are available. This review aims to provide an overview of recent advancements in inducing hematopoietic cells from PSCs, emphasizing the potential implications for future therapeutic interventions.
Indexed as
Identifiers
40587040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.